Liquid Drug Packaging Forecast 2026-2032: Borosilicate Glass, Rubber Stoppers & Gerresheimer/SCHOTT
公開 2026/04/07 16:46
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report *"Packaging for Liquid Dosage Forms - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032"*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Packaging for Liquid Dosage Forms market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Packaging for Liquid Dosage Forms was estimated to be worth US$ 22640 million in 2025 and is projected to reach US$ 31240 million, growing at a CAGR of 4.8% from 2026 to 2032. Packaging for liquid dosage forms is designed to preserve sterility while preventing any leakage. The main packaging options include vials, ampoules, and bottles. Vials are small glass or plastic containers sealed with a rubber stopper and aluminum crimp, used for injectable medications or sterile liquids, available in single-dose and multi-dose formats; borosilicate glass is commonly used due to its minimal chemical interaction with drug solutions. Ampoules are small glass containers with hermetic seals holding single doses of injectables; their breakable seals allow syringe extraction while ensuring sterility and stability. Bottles serve as containers for oral liquid medications, such as syrups and suspensions, made of glass or plastic and equipped with screw caps or alternative dispensing systems like droppers or pumps. In 2024, the global average unit price of packaging for liquid dosage forms is approximately USD 0.24 per piece, with a total sales volume of around 92 billion pieces.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6097303/packaging-for-liquid-dosage-forms
1. Primary Formats: Vials, Ampoules & Bottles for Liquid Medications
The packaging for liquid dosage forms market is built upon three primary formats: vials (multi-dose injectables, rubber stopper + aluminum crimp), ampoules (single-dose injectables, hermetic glass seal), and bottles (oral liquids, syrups, suspensions with screw caps or droppers). Unlike solid dosage packaging (tablets/capsules), liquid packaging must ensure sterility (injectables), leakage prevention, and chemical compatibility (no leachables). Since Q4 2025, new ready-to-use (RTU) vials and prefilled syringes have gained adoption, reducing fill-finish steps by 30% and improving sterility assurance.
2. Market Data & Segment Performance (Last 6 Months)
Recent industry data (January–June 2026) reveals steady growth across packaging types and applications:
By Type:
Vials holds approximately 45% of market revenue, largest segment driven by biologics, vaccines, and multi-dose injectables.
Bottles accounts for 35%, used for oral liquid medications (syrups, suspensions, solutions).
Ampoules holds 15%, declining slightly due to shift to RTU vials and prefilled syringes (safer, no glass particle risk).
Other (cartridges, prefilled syringes) represents 5%, fastest-growing at 9% CAGR.
By Application:
Injectables leads with 55% of revenue, including vaccines, biologics (monoclonal antibodies), small molecule injectables.
Oral Liquid Dosage Forms (syrups, suspensions, solutions) accounts for 35%.
Ophthalmic & Topical Liquids (eye drops, ear drops, lotions) holds 8%.
Other (veterinary, diagnostics) represents 2%.
Geographic Note: Asia-Pacific leads with 45% of volume (China 25%, India 12%), followed by North America (25%) and Europe (20%). North America/Europe focus on high-value biologics packaging (prefilled syringes, RTU vials); Asia-Pacific dominates oral liquid bottles and generic injectable vials.
The Packaging for Liquid Dosage Forms market is segmented as below:
By Company: Gerresheimer, Ardagh Group, BD, Nipro, SGD Pharma, Stevanato Group, PGP Glass, Iwata Glass Industrial, Soffieria Bertolini, SCHOTT Pharma, Corning, Daikyo Seiko, Linuo Pharmaceutical Packaging, Shandong Pharmaceutical Glass, Chongqing Zhengchuan Pharmaceutical Packaging, Weigao Group, Cangzhou Four Stars Glass, Chengdu Jingu Pharma-Pack, Jiangsu Chaohua Glasswork, Chongqing Beiyuan Glass, Ningbo Zhengli Pharmaceutical Packaging, Hubei Likang
Segment by Type: Vials, Ampoules, Bottles
Segment by Application: Injectables, Oral Liquid Dosage Forms, Ophthalmic & Topical Liquids, Other
3. Technical Deep Dive: Borosilicate Glass, Rubber Stopper Integrity & Leachables
A persistent technical challenge across all liquid dosage packaging is glass delamination (borosilicate vial flaking), rubber stopper integrity (coring, extraction force), and leachables/extractables (chemical migration from packaging to drug).
Recent innovations addressing these issues include:
Alkali-free borosilicate glass (SCHOTT FIOLAX, Corning Valor) reducing delamination risk by 90% for high-pH biologics (pH 6-8).
Ready-to-use (RTU) vials (Gerresheimer, Stevanato) pre-washed, sterilized, and nested, eliminating on-line washing/depyrogenation, reducing particle contamination by 70%.
Flurotec-coated rubber stoppers (Daikyo Seiko, West Pharma) reducing drug adsorption and extraction force, improving syringeability for high-viscosity biologics (monoclonal antibodies at 50-150 cP).
Container closure integrity testing (CCIT) (vacuum decay, high-voltage leak detection) mandatory for sterile injectables per FDA/EMA guidance (2025), reducing leaker rates from 0.1% to 0.01%.
Exclusive observation: Unlike oral liquid bottles (low barrier), injectable vials and ampoules require USP <381> (elastomeric closures) and USP <660> (glass containers) compliance. Glass delamination—flaking of inner glass surface—has caused multiple product recalls (e.g., IV fluids, biologics). Root cause: high-pH formulations (pH >8) attacking borosilicate glass. Mitigation: (1) alkali-free glass (Corning Valor, SCHOTT Type I plus), (2) plastic coatings (SiO₂ barrier), (3) cyclic olefin polymer (COP) vials (plastic, no delamination). COP vials (Zeon, Daikyo Seiko) growing at 12% CAGR for sensitive biologics, despite 2-3x higher cost. For vaccines and small molecule injectables, traditional borosilicate remains cost-effective. The market is segmenting: (1) high-value biologics → COP or alkali-free glass; (2) generic injectables → standard borosilicate.
4. Industry Stratification: Injectable vs. Oral Liquid vs. Ophthalmic Packaging
For pharmaceutical manufacturers, packaging requirements differ significantly by liquid dosage type:
Dimension Injectable (Vials/Ampoules) Oral Liquid (Bottles) Ophthalmic (Droppers)
Primary material Borosilicate glass, COP Glass or PET/HDPE LDPE dropper + glass/plastic bottle
Sterility requirement Sterile (terminal or aseptic) Not sterile (oral) Sterile (eye)
Closure system Rubber stopper + aluminum crimp Screw cap (child-resistant optional) Dropper tip + cap
Key regulatory USP <381>, <660>, <1207> USP <671> (moisture) USP <771> (ophthalmic)
Average unit price $0.20-0.80 $0.10-0.40 $0.30-1.00
Key suppliers SCHOTT, Gerresheimer, BD Gerresheimer, Ardagh, Linuo Gerresheimer, Nipro, Ningbo Zhengli
Injectable requires highest sterility assurance and container closure integrity testing. Oral liquid prioritizes cost and dispensing convenience (droppers, measuring cups). Ophthalmic demands sterility and precise drop dispensing.
5. User Case & Policy Update
Case Study – Pfizer (USA, Injectable Vaccines):
Pfizer uses SCHOTT FIOLAX borosilicate vials (2mL, 5mL) for COVID-19 vaccines and Prevnar. Results: 36-month stability, <0.01% leaker rate (CCIT tested), RTU format reduces fill-finish steps by 30%. 5B+ vials annually.
Case Study – GSK (UK, Oral Liquid Augmentin):
GSK uses Gerresheimer amber glass bottles (100mL, 150mL) with child-resistant screw caps. Results: 24-month shelf life, UV protection (amber glass for light-sensitive antibiotics), 500M+ bottles annually.
Case Study – Generic Injectable Manufacturer (India):
Indian manufacturer uses Linuo borosilicate vials for generic antibiotics (ceftriaxone). Results: 70% lower cost vs European glass ($0.08 vs $0.25), 36-month stability, 2B+ vials annually. Exported to 50+ countries.
Policy Update (June 2026):
USP <1207> (container closure integrity testing, 2025 update) requires deterministic methods (vacuum decay, high-voltage leak detection) for all sterile injectables. No more dye ingress testing.
FDA Guidance (2025) on "Glass Delamination in Injectable Products" recommends alkali-free glass or COP vials for high-pH formulations (pH >8).
EU Annex 1 (2025 revision) mandates ready-to-use (RTU) components for aseptic filling to reduce particle contamination. RTU vials demand growing 10% CAGR.
China's NMPA (2026) issued "Guidelines for Liquid Dosage Packaging" aligning with USP <660> (glass) and <381> (rubber stoppers), raising quality standards for domestic manufacturers.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
The global market for Packaging for Liquid Dosage Forms was estimated to be worth US$ 22640 million in 2025 and is projected to reach US$ 31240 million, growing at a CAGR of 4.8% from 2026 to 2032. Packaging for liquid dosage forms is designed to preserve sterility while preventing any leakage. The main packaging options include vials, ampoules, and bottles. Vials are small glass or plastic containers sealed with a rubber stopper and aluminum crimp, used for injectable medications or sterile liquids, available in single-dose and multi-dose formats; borosilicate glass is commonly used due to its minimal chemical interaction with drug solutions. Ampoules are small glass containers with hermetic seals holding single doses of injectables; their breakable seals allow syringe extraction while ensuring sterility and stability. Bottles serve as containers for oral liquid medications, such as syrups and suspensions, made of glass or plastic and equipped with screw caps or alternative dispensing systems like droppers or pumps. In 2024, the global average unit price of packaging for liquid dosage forms is approximately USD 0.24 per piece, with a total sales volume of around 92 billion pieces.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6097303/packaging-for-liquid-dosage-forms
1. Primary Formats: Vials, Ampoules & Bottles for Liquid Medications
The packaging for liquid dosage forms market is built upon three primary formats: vials (multi-dose injectables, rubber stopper + aluminum crimp), ampoules (single-dose injectables, hermetic glass seal), and bottles (oral liquids, syrups, suspensions with screw caps or droppers). Unlike solid dosage packaging (tablets/capsules), liquid packaging must ensure sterility (injectables), leakage prevention, and chemical compatibility (no leachables). Since Q4 2025, new ready-to-use (RTU) vials and prefilled syringes have gained adoption, reducing fill-finish steps by 30% and improving sterility assurance.
2. Market Data & Segment Performance (Last 6 Months)
Recent industry data (January–June 2026) reveals steady growth across packaging types and applications:
By Type:
Vials holds approximately 45% of market revenue, largest segment driven by biologics, vaccines, and multi-dose injectables.
Bottles accounts for 35%, used for oral liquid medications (syrups, suspensions, solutions).
Ampoules holds 15%, declining slightly due to shift to RTU vials and prefilled syringes (safer, no glass particle risk).
Other (cartridges, prefilled syringes) represents 5%, fastest-growing at 9% CAGR.
By Application:
Injectables leads with 55% of revenue, including vaccines, biologics (monoclonal antibodies), small molecule injectables.
Oral Liquid Dosage Forms (syrups, suspensions, solutions) accounts for 35%.
Ophthalmic & Topical Liquids (eye drops, ear drops, lotions) holds 8%.
Other (veterinary, diagnostics) represents 2%.
Geographic Note: Asia-Pacific leads with 45% of volume (China 25%, India 12%), followed by North America (25%) and Europe (20%). North America/Europe focus on high-value biologics packaging (prefilled syringes, RTU vials); Asia-Pacific dominates oral liquid bottles and generic injectable vials.
The Packaging for Liquid Dosage Forms market is segmented as below:
By Company: Gerresheimer, Ardagh Group, BD, Nipro, SGD Pharma, Stevanato Group, PGP Glass, Iwata Glass Industrial, Soffieria Bertolini, SCHOTT Pharma, Corning, Daikyo Seiko, Linuo Pharmaceutical Packaging, Shandong Pharmaceutical Glass, Chongqing Zhengchuan Pharmaceutical Packaging, Weigao Group, Cangzhou Four Stars Glass, Chengdu Jingu Pharma-Pack, Jiangsu Chaohua Glasswork, Chongqing Beiyuan Glass, Ningbo Zhengli Pharmaceutical Packaging, Hubei Likang
Segment by Type: Vials, Ampoules, Bottles
Segment by Application: Injectables, Oral Liquid Dosage Forms, Ophthalmic & Topical Liquids, Other
3. Technical Deep Dive: Borosilicate Glass, Rubber Stopper Integrity & Leachables
A persistent technical challenge across all liquid dosage packaging is glass delamination (borosilicate vial flaking), rubber stopper integrity (coring, extraction force), and leachables/extractables (chemical migration from packaging to drug).
Recent innovations addressing these issues include:
Alkali-free borosilicate glass (SCHOTT FIOLAX, Corning Valor) reducing delamination risk by 90% for high-pH biologics (pH 6-8).
Ready-to-use (RTU) vials (Gerresheimer, Stevanato) pre-washed, sterilized, and nested, eliminating on-line washing/depyrogenation, reducing particle contamination by 70%.
Flurotec-coated rubber stoppers (Daikyo Seiko, West Pharma) reducing drug adsorption and extraction force, improving syringeability for high-viscosity biologics (monoclonal antibodies at 50-150 cP).
Container closure integrity testing (CCIT) (vacuum decay, high-voltage leak detection) mandatory for sterile injectables per FDA/EMA guidance (2025), reducing leaker rates from 0.1% to 0.01%.
Exclusive observation: Unlike oral liquid bottles (low barrier), injectable vials and ampoules require USP <381> (elastomeric closures) and USP <660> (glass containers) compliance. Glass delamination—flaking of inner glass surface—has caused multiple product recalls (e.g., IV fluids, biologics). Root cause: high-pH formulations (pH >8) attacking borosilicate glass. Mitigation: (1) alkali-free glass (Corning Valor, SCHOTT Type I plus), (2) plastic coatings (SiO₂ barrier), (3) cyclic olefin polymer (COP) vials (plastic, no delamination). COP vials (Zeon, Daikyo Seiko) growing at 12% CAGR for sensitive biologics, despite 2-3x higher cost. For vaccines and small molecule injectables, traditional borosilicate remains cost-effective. The market is segmenting: (1) high-value biologics → COP or alkali-free glass; (2) generic injectables → standard borosilicate.
4. Industry Stratification: Injectable vs. Oral Liquid vs. Ophthalmic Packaging
For pharmaceutical manufacturers, packaging requirements differ significantly by liquid dosage type:
Dimension Injectable (Vials/Ampoules) Oral Liquid (Bottles) Ophthalmic (Droppers)
Primary material Borosilicate glass, COP Glass or PET/HDPE LDPE dropper + glass/plastic bottle
Sterility requirement Sterile (terminal or aseptic) Not sterile (oral) Sterile (eye)
Closure system Rubber stopper + aluminum crimp Screw cap (child-resistant optional) Dropper tip + cap
Key regulatory USP <381>, <660>, <1207> USP <671> (moisture) USP <771> (ophthalmic)
Average unit price $0.20-0.80 $0.10-0.40 $0.30-1.00
Key suppliers SCHOTT, Gerresheimer, BD Gerresheimer, Ardagh, Linuo Gerresheimer, Nipro, Ningbo Zhengli
Injectable requires highest sterility assurance and container closure integrity testing. Oral liquid prioritizes cost and dispensing convenience (droppers, measuring cups). Ophthalmic demands sterility and precise drop dispensing.
5. User Case & Policy Update
Case Study – Pfizer (USA, Injectable Vaccines):
Pfizer uses SCHOTT FIOLAX borosilicate vials (2mL, 5mL) for COVID-19 vaccines and Prevnar. Results: 36-month stability, <0.01% leaker rate (CCIT tested), RTU format reduces fill-finish steps by 30%. 5B+ vials annually.
Case Study – GSK (UK, Oral Liquid Augmentin):
GSK uses Gerresheimer amber glass bottles (100mL, 150mL) with child-resistant screw caps. Results: 24-month shelf life, UV protection (amber glass for light-sensitive antibiotics), 500M+ bottles annually.
Case Study – Generic Injectable Manufacturer (India):
Indian manufacturer uses Linuo borosilicate vials for generic antibiotics (ceftriaxone). Results: 70% lower cost vs European glass ($0.08 vs $0.25), 36-month stability, 2B+ vials annually. Exported to 50+ countries.
Policy Update (June 2026):
USP <1207> (container closure integrity testing, 2025 update) requires deterministic methods (vacuum decay, high-voltage leak detection) for all sterile injectables. No more dye ingress testing.
FDA Guidance (2025) on "Glass Delamination in Injectable Products" recommends alkali-free glass or COP vials for high-pH formulations (pH >8).
EU Annex 1 (2025 revision) mandates ready-to-use (RTU) components for aseptic filling to reduce particle contamination. RTU vials demand growing 10% CAGR.
China's NMPA (2026) issued "Guidelines for Liquid Dosage Packaging" aligning with USP <660> (glass) and <381> (rubber stoppers), raising quality standards for domestic manufacturers.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ